GRENOBLE, France and PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS ("Koelis" or the "Company", www.koelis.com), a global leader and innovator in prostate care, announced today the ...
Prostate cancer is one of the most common cancers and the second leading cause of cancer-related death in men in the U.S. The American Cancer Society estimates there were 192,000 new cases last year ...
A new review in Medical Oncology details how liquid biomarkers, advanced imaging, and artificial intelligence are transforming pre-biopsy discrimination of prostate cancer from benign disease.
Test aims to help clinicians decide whether patients who test negative will need further biopsy procedures. FDA approved Gen-Probe’s Progensa® PCA3 (Prostate Cancer gene 3) assay, which the firm ...
A cancer imaging agent that was originally developed at Emory University was approved on Friday, May 27 by the U.S. Food and Drug Administration. Axumin, a PET (positron emission tomography) imaging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results